Interactions with Ibalizumab

initiated within 9 months after stopping subcutaneous LEN. Residual LEN may affect exposure of sensitive CYP3A4 substrates

Fluorouracil
Cytarabine
Cyclophosphamide
Doxorubicin
Daunorubicin
Epirubicin

Antimetabolite Agents

Antitumour Antibiotics

Bleomycin
Daunorubicin
Doxorubicin
Epirubicin

Alkylating Agents

Carboplatin
Chlorambucil
Cisplatin
Cyclophosphamide
Decarbazepine
Dacarbazine
Dacarbazine
Ifosfamide
Oxaliplatin
Procarbazine

Antimetabolite Agents

Capecitabine
Cytarabine
Fluorouracil
Gemcitabine
Mercaptopurine
Methotrexate

Interactions with CAB/RPV long acting injections
Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

Interactions with Lenacapavir
Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

Interactions with Ibalizumab
None

Notes

a Cytoplastic agent may induce cancer toxicity including arrhythmias and/or non-specific ECG abnormalities; caution is warranted in presence of other drugs with potential effects on PR and QT intervals.

b Potential additive nephrotoxicity

c Carboplatin may impair renal function: monitor creatinine clearance and adjust NRTI dosage accordingly (may require a change from a single tablet regimen).

d Coadministration may increase concentrations of cisplatin and FTC. Close monitoring of renal function is recommended.

e Concentrations of parent drug decreased but concentrations of the active metabolite increased.

f Concentrations of parent drug decreased but concentrations of the active metabolite and toxic metabolite increased.

g Concentrations of dacarbazine and tenofovir may increase. Close monitoring of renal function is recommended.

h Concentrations of parent drug increased but concentrations of the active metabolite decreased which may result in decreased efficacy.

i Coadministration may affect bevacizumab concentrations. In addition, ifosfamide and tenofovir alafenamide may add oxidative renal toxicity.

j The oxaliplatin effect may be potentially antagonised due to its reduced entry into the tumour cell arising from the inhibition of OCT2.

k Use in HIV patients is contraindicated by some manufacturers.
**Plant Alkaloids**

<table>
<thead>
<tr>
<th></th>
<th>AT/IVc</th>
<th>AT/IVr</th>
<th>DRV/IVc</th>
<th>DRV/IVr</th>
<th>LPV/IVr</th>
<th>LPV/IVr</th>
<th>EFV</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>RPV oral</th>
<th>FTR</th>
<th>LEN</th>
<th>MVC</th>
<th>BIC/FTV/DF</th>
<th>CAB oral</th>
<th>CAB/ RPV</th>
<th>DTG</th>
<th>EVG/c/FTDF</th>
<th>EVG/c/FTVDF</th>
<th>RAL</th>
<th>FTC/ TAF</th>
<th>FTC/ TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Docetaxel</td>
<td>↑ ↑ ↑ ↑</td>
<td>↑ ↑ ↑ ↑</td>
<td>↓ ↓ ↓</td>
<td>↓ ↓ ↓</td>
<td>↑ ↑ ↑ ↑</td>
<td>↑ ↑ ↑ ↑</td>
<td>↑ ↑ ↑ ↑</td>
<td>↑ ↑ ↑ ↑</td>
<td></td>
<td></td>
<td>♡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>▼ ▼ ▼</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eribulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinblastine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tyrosine Kinase Inhibitors**

<table>
<thead>
<tr>
<th></th>
<th>AT/IVc</th>
<th>AT/IVr</th>
<th>DRV/IVc</th>
<th>DRV/IVr</th>
<th>LPV/IVr</th>
<th>LPV/IVr</th>
<th>EFV</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>RPV oral</th>
<th>FTR</th>
<th>LEN</th>
<th>MVC</th>
<th>BIC/FTV/DF</th>
<th>CAB oral</th>
<th>CAB/ RPV</th>
<th>DTG</th>
<th>EVG/c/FTDF</th>
<th>EVG/c/FTVDF</th>
<th>RAL</th>
<th>FTC/ TAF</th>
<th>FTC/ TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dasatinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erlotinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gefitinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ixazomib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lapatinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pazopanib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raml nim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Interactions with CAB/RPV long acting injections**

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

**Interactions with Lenacapvir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**

None

---

**Colour Legend**

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity.
- No a priori dosage adjustment is recommended.

**Text Legend**

- Potential increased exposure of the cancer drug
- Potential decreased exposure of the cancer drug
- No significant effect
- One or both drugs may cause QT and/or PR prolongation. ECG monitoring is advised if coadministered with atazanavir or lopinavir.
- Efavirenz has a potential risk of QT prolongation relating specifically to homozgyous carriers of CYP2B6*6/*6. Rilpivirine and fostemsavir were shown to prolong the QT interval at supratherapeutic doses. Caution is advised with rilpivirine. ECG monitoring is advised with fostemsavir and drugs with a known QT prolongation risk.
- Potential QT and/or PR prolongation due to the cytostatic agent. Use with caution; ECG monitoring recommended.

**Notes**

- a Concentrations of SN-38 (active metabolite) increased.
- b Coadministration is contraindicated in the atazanavir US product label, but the European product label recommends patients should be closely monitored for adverse reactions related to irinotecan.
- c Conversion of SN-38 to inactive metabolite increased.
- d Coadministration may decrease bictegravir concentrations, but no effect on emtricitabine or tenofovir alafenamide is expected.
### Cancer Therapies Treatment Select (3)

**ATV/c** | **ATV/r** | **DRV/c** | **DRV/r** | **LPV/r** | **DOR** | **EFV** | **ETV** | **NVP** | **RPV** | **FTR** | **LEN** | **MVC** | **BIC/ F/TAF** | **CAB** | **CAB/ RPV** | **DTG** | **EVL/ F/TAF** | **EVL/ F/TDF** | **RAL** | **FTC/ TAF** | **FTG/ TDF**
**Others**

| Abiraterone | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Avelumab | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Bortezomib | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** | **↓** |
| Brentuximab vedotin | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Cetuximab | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Enzalutamide | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** | **↑** |
| Everolimus | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Polatuzumab vedotin | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Sorafenib | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Tamoxifen | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Temsirolimus | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Trastuzumab | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |
| Trastuzumab emtansine | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** | **↔** |

**Interactions with CAB/RPV long acting injections**

Pharmacokinetic interactions shown are mostly with RPV.

**Interactions with Lenacapavir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**

None

<table>
<thead>
<tr>
<th>Colour Legend</th>
<th>Text Legend</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Potential increased exposure of the cancer drug</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Potential decreased exposure of the cancer drug</strong></td>
</tr>
<tr>
<td></td>
<td><strong>No significant effect</strong></td>
</tr>
<tr>
<td></td>
<td><strong>One or both drugs may cause QT and/or PR prolongation. ECG monitoring is advised if coadministered with atazanavir or lopinavir.</strong></td>
</tr>
<tr>
<td></td>
<td>**Efavirenz has a potential risk of QT prolongation relating specifically to homozygous carriers of CYP2B6<em>6/<em>6.</em></em></td>
</tr>
<tr>
<td></td>
<td><strong>Rilpivirine and fosampire were shown to prolong the QT interval at supratherapeutic doses. Caution is advised with rilpivirine. ECG monitoring is advised with fosampire and drugs with a known QT prolongation risk.</strong></td>
</tr>
</tbody>
</table>

**Notes**

a. Brentuximab vedotin and polatuzumab vedotin are antibody-drug conjugates comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent and a substrate of CYP3A4 and P-gp. Coadministration may increase concentrations of MMAE and the incidence of neutropenia. Patients should be closely monitored for toxicities.

b. Brentuximab vedotin and polatuzumab vedotin are antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent and a substrate of CYP3A4 and P-gp. Coadministration may decrease concentrations of MMAE but no a priori dose adjustment is necessary as the contribution of free MMAE to efficacy is minimal.

c. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks (but preferably 4 weeks) cessation period is recommended prior to initiation of lenacapavir due to the persisting inducing effect upon discontinuation of a strong inducer.

d. Consider increasing maraviroc to 600 mg twice daily in the presence of enzalutamide. Enzalutamide has a long half-life (5.8 days), therefore the maraviroc dose should be kept at 600 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.

e. Dolastegavir should be administered at 50 mg twice daily in the absence of integrase class resistance. In the presence of integrase class resistance this combination should be avoided. Enzalutamide has a long half-life (5.8 days), therefore the dolastegavir dose should be kept at 50 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.

f. Consider increasing raltegravir dose to 800 mg twice daily when coadministering with enzalutamide. Coadministration of once daily raltegravir is not recommended. Enzalutamide has a long half-life (5.8 days), therefore the raltegravir dose should be kept at 800 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.

g. Poor tolerability has been observed in patients on ronitazoc-containing regimens. (A similar effect may also occur with cobicistat-containing regimens.

h. Potential additive nephrotoxicity with sorafenib and tenofovir-D. Monitor renal function if coadministered or consider an alternate antiretroviral regimen if possible.

i. Concentrations of parent drug increased but concentrations of the active metabolite decreased which may result in decreased efficacy.

j. Concentrations of parent drug decreased but concentrations of the active metabolite increased.

k. Coadministration not recommended due to the potential for an increase in exposure and toxicity of DM1 (an active component of emtansine).

l. Potential increase in exposure and toxicity of DM1 (an active component of emtansine).